Drugs / OP-724
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04688034 | Mar 2021 → Jul 2022 | cirrhosis of liver | Kiminori Kimura, MD | Completed | No outcome recorded |
| Phase 1 | NCT04047160 | Aug 2019 → Sep 2021 | primary biliary cholangitis | Kiminori Kimura, MD | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OP-724 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04047160 ↗ |
| Action | Inhibit | “a CREB-binding protein/β-catenin inhibitor” PMID 36442892 ↗ Nov 2022 |
| Route | Intravenous | “Seven patients received intravenous OP-724 infusions at escalating dosages of 280 and 380 mg/m2/4 hours two times weekly for 12 weeks.” PMID 36442892 ↗ Nov 2022 |